

Resource Summary Report

Generated by SPARC SAWG on Sep 16, 2026

Celgene

RRID:SCR_002955

Type: Tool

Proper Citation

Celgene (RRID:SCR_002955)

Resource Information

URL: <http://www.celgene.com>

Proper Citation: Celgene (RRID:SCR_002955)

Description: An American global biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). (Adapted from Wikipedia) There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.

Abbreviations: CELG

Synonyms: Celgene Corporation

Resource Type: commercial organization

Keywords: biopharmaceutical, drug, immune, inflammatory, clinical, medical, hematological, tumor, myeloma, myelodysplastic, syndrome, lymphocyte, leukemia, lymphoma, glioblastoma, ovarian, pancreatic, prostate, medicine, biotechnology

Related Condition: Cancer, Immune disease, Inflammatory disease, Attention-Deficit Hyperactivity Disorder

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Celgene

Resource ID: SCR_002955

Alternate IDs: nif-0000-30309

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260912T195549+0000

Ratings and Alerts

No rating or validation information has been found for Celgene.

No alerts have been found for Celgene.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 52 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Chi KN, et al. (2025) rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. Future oncology (London, England), 21(14), 1771.

Rasmussen B, et al. (2025) Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes, chromosomes & cancer, 64(2), e70029.

Thoms JAI, et al. (2025) Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs. Nature communications, 16(1), 4451.

Blauvelt A, et al. (2024) Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA dermatology, 160(8), 856.

Shinoda S, et al. (2023) Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Cancer science, 114(9), 3759.

Coulson AB, et al. (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. *BMJ open*, 12(6), e056147.

Royle KL, et al. (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. *BMJ open*, 12(11), e063037.

Marchand A, et al. (2022) Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes. *Drug testing and analysis*, 14(11-12), 1952.

Shimizu N, et al. (2021) PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates. *Communications biology*, 4(1), 1277.

Jackson GH, et al. (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. *PLoS medicine*, 18(1), e1003454.

Hwang D, et al. (2021) Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane® in rodent and non-human primate models using a stable isotope tracer assay. *Biomaterials*, 278, 121140.

Wallis RS, et al. (2021) Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. *The Lancet. Respiratory medicine*, 9(8), 897.

Danziger SA, et al. (2020) Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. *PLoS medicine*, 17(11), e1003323.

Routray R, et al. (2020) Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination. *Drug safety*, 43(1), 57.

Carballido JM, et al. (2020) The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. *Frontiers in immunology*, 11, 472.

Romano A, et al. (2020) High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling. *Scientific reports*, 10(1), 1983.

Romero Pérez A, et al. (2020) Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. *PloS one*, 15(6), e0234556.

Brekke OL, et al. (2019) Key role of the number of complement receptor 1 on erythrocytes for binding of *Escherichia coli* to erythrocytes and for leukocyte phagocytosis and oxidative burst in human whole blood. *Molecular immunology*, 114, 139.

Terebelo HR, et al. (2019) Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. British journal of haematology, 187(5), 602.

Li Y, et al. (2019) An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics. Clinical pharmacology in drug development, 8(3), 346.